1. Market Research
  2. > Diamyd Medical AB – Product Pipeline Review – 2013

Diamyd Medical AB – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 54 pages

Diamyd Medical AB – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Diamyd Medical AB - Product Pipeline Review - 2013” provides data on the Diamyd Medical AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Diamyd Medical AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Diamyd Medical AB and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Diamyd Medical AB - Brief Diamyd Medical AB overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Diamyd Medical AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Diamyd Medical AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Diamyd Medical AB’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Diamyd Medical AB’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Diamyd Medical AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Diamyd Medical AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Diamyd Medical AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Diamyd Medical AB and identify potential opportunities in those areas.

Table Of Contents

Diamyd Medical AB - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Diamyd Medical AB Snapshot 5
Diamyd Medical AB Overview 5
Key Information 5
Key Facts 5
Diamyd Medical AB - Research and Development Overview 6
Key Therapeutic Areas 6
Diamyd Medical AB - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Diamyd Medical AB - Pipeline Products Glance 10
Diamyd Medical AB Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Diamyd Medical AB - Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Diamyd Medical AB - Drug Profiles 12
Diamyd 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
NC-3 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
NE2 Endomorphin 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
NG2-GAD 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
NN1 Neurotrophin 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
NP-2 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Diamyd Medical AB - Pipeline Products by Route of Administration 21
Diamyd Medical AB - Pipeline Products By Mechanism of Action 22
Diamyd Medical AB - Recent Pipeline Updates 23
Diamyd Medical AB - Dormant Projects 27
Diamyd Medical AB - Company Statement 28
Diamyd Medical AB - Locations And Subsidiaries 30
Head Office 30
Other Locations and Subsidiaries 30
Diamyd Medical AB, Recent Developments 31
Diamyd Medical AB- Press Release 31
Jan 30, 2013: Diamyd Medical To Start New Clinical Study With Diabetes Vaccine 31
Nov 10, 2010: Diamyd Completes Screening For US Phase III study 32
Oct 19, 2010: Diamyd Reports Data From Chronic Pain Trial With NP2 Enkephalin 32
Oct 19, 2010: Diamyd Trial In Chronic Pain Shows Pain Relief 33
Sep 13, 2010: Diamyd Reports Promising Safety Findings From Phase I Study In Chronic Pain 34
Mar 24, 2010: Diamyd Medical Receives Orphan Drug Designation For Diamyd In US 34
Mar 10, 2010: Diamyd Medical Enrolls 100 Patients In Ongoing US Phase III Study Of Diabetes Drug 35
Jan 29, 2010: Diamyd To File Market Approval For The Diamyd Diabetes Vaccine In 2011 35
Financial Deals Landscape 37
Diamyd Medical AB, Deals Summary 37
Diamyd Medical AB, Pharmaceuticals and Healthcare, Deal Details 38
Partnerships 38
Diamyd Medical Enters Into Co-Development Agreement With Ortho-McNeil-Janssen 38
Diamyd Medical Enters Into Agreement With NIDDK 40
Licensing Agreements 41
Diamyd Medical Enters Into Licensing Agreement For Endomorphin Technology 41
Equity Offering 42
Diamyd Medical Completes Private Placement Of $5 Million 42
Diamyd Medical Completes Rights Issue Of $31 Million 44
Diamyd Medical Raises $3 Million From Excise Of Warrants 46
Diamyd Medical Completes Private Placement Of $12 Million 48
Debt Offering 50
Protein Sciences Completes Private Placement Of Convertible Notes For $1 Million 50
Acquisition 51
Periphagen Completes Acquisition Of Diamyd Medical's Subsidary 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54



List of Tables

Diamyd Medical AB, Key Information 5
Diamyd Medical AB, Key Facts 5
Diamyd Medical AB - Pipeline by Indication, 2013 7
Diamyd Medical AB - Pipeline by Stage of Development, 2013 8
Diamyd Medical AB - Monotherapy Products in Pipeline, 2013 9
Diamyd Medical AB - Phase II, 2013 10
Diamyd Medical AB - Pre-Clinical, 2013 11
Diamyd Medical AB - Pipeline By Route of Administration, 2013 21
Diamyd Medical AB - Pipeline Products By Mechanism of Action, 2013 22
Diamyd Medical AB - Recent Pipeline Updates, 2013 23
Diamyd Medical AB - Dormant Developmental Projects,2013 27
Diamyd Medical AB, Subsidiaries 30
Diamyd Medical AB, Deals Summary 37
Diamyd Medical Enters Into Co-Development Agreement With Ortho-McNeil-Janssen 38
Diamyd Medical Enters Into Agreement With NIDDK 40
Diamyd Medical Enters Into Licensing Agreement For Endomorphin Technology 41
Diamyd Medical Completes Private Placement Of $5 Million 42
Diamyd Medical Completes Rights Issue Of $31 Million 44
Diamyd Medical Raises $3 Million From Excise Of Warrants 46
Diamyd Medical Completes Private Placement Of $12 Million 48
Protein Sciences Completes Private Placement Of Convertible Notes For $1 Million 50
Periphagen Completes Acquisition Of Diamyd Medical's Subsidary 51



List of Figures

Diamyd Medical AB - Pipeline by Indication, 2013 7
Diamyd Medical AB - Pipeline by Stage of Development, 2013 8
Diamyd Medical AB - Monotherapy Products in Pipeline, 2013 9
Diamyd Medical AB - Pipeline By Route of Administration, 2013 21
Diamyd Medical AB - Pipeline Products By Mechanism of Action, 2013 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.